Solomon D. Kattar - Concepedia

Author

Solomon D. Kattar

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Kattar, Sam, Kattar, Solomon, Sam D. Kattar, Sam Kattar, Solomon D. Kattar, Solomon Kattar

Publications

471

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy

About

Solomon D. Kattar is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, drug discovery, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	101
2	Natural Sciences	4	4	101
3	Chemical Biology	3	3	86
4	Biochemistry	2	2	68
5	Immunology	1	1	15

Solomon D. Kattar

Publications

341

Citations

H-Index

Page 1

	Year	Citations
Neurofilaments Consist of Distinct Populations That Can Be Distinguished by C-Terminal Phosphorylation, Bundling, and Axonal Transport Rate in Growing Axonal Neurites Jason T. Yabe, Teresa M. Chylinski, Feng-Song Wang, Journal of Neuroscience	2001	110
Piperazinyl pyrimidine derivatives as potent γ-secretase modulators Alexey Rivkin, Sean P. Ahearn, Stephanie M. Chichetti, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryBiochemistryNatural SciencesMedicine	2009	41
Discovery of a chemical probe for PRDM9 Abdellah Allali‐Hassani, Magdalena M. Szewczyk, Danton Ivanochko, Nature Communications	2019	41
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar, Journal of Medicinal Chemistry	2021	40
Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization Solomon D. Kattar, Laura Surdi, Anna A. Zabierek, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPharmaceutical SciencePharmaceutical ChemistryBiochemistryMedicine	2008	27
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease David A. Candito, Vladimir Simov, Anmol Gulati, Journal of Medicinal Chemistry	2022	19
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow Xavier Fradera, Joey L. Methot, Abdelghani Achab, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistrySelective Pi3kδ InhibitorsMedicineNatural SciencesPharmacology	2019	18
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson’s Disease Solomon D. Kattar, Anmol Gulati, Kaila A. Margrey, Journal of Medicinal Chemistry	2023	16
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability Joey L. Methot, Hua Zhou, Solomon D. Kattar, Journal of Medicinal Chemistry Purine Pi3kδ InhibitorImmunologyMolecular BiologyStructure Overhaul AffordsPharmacotherapy	2019	15
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors Anmol Gulati, Charles S. Yeung, Blair T. Lapointe, RSC Medicinal Chemistry	2021	14

Page 1